Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Oct 5;149(1):111–120. doi: 10.1093/toxsci/kfv213

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Published by Oxford University Press on behalf of the Society of Toxicology 2015. This work is written by US Government employees and is in the public domain in the US.

PMC Copyright notice

FIG. 2. — CDDO-EA treatment reduces complication of end stage liver disease and improves mortality. A, Representative ascites photograph at week 30 in CCl₄ treated group. Longitudinal graph shows percentage of ascites formation. Histogram shows relative weight of soaked ascites paper (middle panel) whereas right panel depicts event noted per group for the formation of ascites. B. Representative photograph of gross livers from mice at week 30 post treatment of CCl₄ plus CDDO-EA. Histogram depicts average number of tumors identified per group. Data are presented as mean ± SE (n = 10 per group). Longitudinal graph shows percentage of HCC formation after CCl₄ treatment for 12 weeks followed by 18 more weeks of CDDO-EA. C. Liver function test over time in CDDO-EA treated versus nontreated. Data represent mean ± SE (n = 20 per time point). D, CCl₄ treated mice had > 70% mortality after 30 weeks while addition of CDDO-EA at week 12 had < 20% mortality during the same period of time. (N = 40 per group). *P < .05, **P < .01, ***P < .001.